Literature DB >> 8325342

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

F Martinon1, S Krishnan, G Lenzen, R Magné, E Gomard, J G Guillet, J P Lévy, P Meulien.   

Abstract

The induction of anti-influenza cytotoxic T lymphocytes (CTL) in vivo by immunizing mice with liposomes containing messenger RNA (mRNA) encoding the influenza virus nucleoprotein (NP) is described. NP mRNA, obtained by in vitro transcription, was encapsulated into simple cholesterol/phosphatidylcholine/phosphatidylserine liposomes by the detergent removal technique. The dependence of the route of mRNA-liposomes delivery on CTL induction was studied. The CTL induced were identical to those obtained in vivo with infectious virus in terms of specificity, lysing both peptide-sensitized and virus-infected targets. Furthermore, with the same mRNA-liposome preparation, virus-specific CTL responses could be also elicited in mice of three different haplotypes each of them known to present a distinct NP peptide in an MHC-restricted fashion. The relevance of these results in the context of vaccine development is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325342     DOI: 10.1002/eji.1830230749

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  109 in total

Review 1.  RNA-transfected dendritic cells in cancer immunotherapy.

Authors:  D A Mitchell; S K Nair
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines.

Authors:  Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2003-12-02       Impact factor: 4.599

3.  Virus-specific cytotoxic T-lymphocyte activity elicited by coimmunization with human immunodeficiency virus type 1 genes regulated by the bacteriophage T7 promoter and T7 RNA polymerase protein.

Authors:  M J Selby; B Doe; C M Walker
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

Review 5.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

6.  How COVID unlocked the power of RNA vaccines.

Authors:  Elie Dolgin
Journal:  Nature       Date:  2021-01       Impact factor: 49.962

Review 7.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

8.  Nonviral delivery of self-amplifying RNA vaccines.

Authors:  Andrew J Geall; Ayush Verma; Gillis R Otten; Christine A Shaw; Armin Hekele; Kaustuv Banerjee; Yen Cu; Clayton W Beard; Luis A Brito; Thomas Krucker; Derek T O'Hagan; Manmohan Singh; Peter W Mason; Nicholas M Valiante; Philip R Dormitzer; Susan W Barnett; Rino Rappuoli; Jeffrey B Ulmer; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

9.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.

Authors:  Matthias A Oberli; Andreas M Reichmuth; J Robert Dorkin; Michael J Mitchell; Owen S Fenton; Ana Jaklenec; Daniel G Anderson; Robert Langer; Daniel Blankschtein
Journal:  Nano Lett       Date:  2016-12-05       Impact factor: 11.189

Review 10.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.